Stock events for MiMedx Group, Inc. (MDXG)
MiMedx Group's stock has been influenced by several events in the past six months. The company announced its first-quarter 2025 results with a 4% YoY net sales increase and second-quarter 2025 results with a 13% YoY revenue growth. EPIXPRESS was launched on October 6, 2025. Wall Street Zen downgraded MiMedx Group from a "strong-buy" to a "buy" rating on October 25, 2025, and Weiss Ratings reissued a "Hold (C)" rating on October 27, 2025. Cantor Fitzgerald boosted its target price for MiMedx Group from $11.00 to $12.00 and maintained an "overweight" rating on July 31, 2025. Institutional investors were reportedly rewarded after a US$56 million market cap gain in the week leading up to October 7, 2025. As of October 21, 2025, the stock price was $6.74, marking a 17.83% increase from October 22, 2024, and gained 1.81% on October 24, 2025.
Demand Seasonality affecting MiMedx Group, Inc.’s stock price
Specific detailed information regarding the demand seasonality for MiMedx Group, Inc.'s products and services is not readily available. Demand may be influenced by healthcare spending cycles, the prevalence of chronic wounds, and the volume of surgical and sports medicine procedures.
Overview of MiMedx Group, Inc.’s business
MiMedx Group, Inc. is a biotechnology company specializing in regenerative medicine, focusing on placental tissue allografts. The company uses its PURION process to create products that reduce inflammation, minimize scarring, and enhance tissue healing. Its products, including EpiFix and AmnioFix, serve the wound care, burn, surgical, and sports medicine sectors.
MDXG’s Geographic footprint
MiMedx Group, Inc. primarily operates in the United States, selling its products through a direct sales force, independent sales agents, and distributors to healthcare professionals in hospitals, surgical centers, and physician offices.
MDXG Corporate Image Assessment
MiMedx Group's brand reputation has been influenced by its innovative standing in regenerative medicine, alongside challenges related to Medicare reimbursement. The company is recognized for its innovative approach and best-in-class products. However, challenges related to alleged abuse of the Medicare reimbursement system have impacted the company's reputation. The company is committed to advocating for improvements in pricing and clinical data requirements with CMS and other stakeholders.
Ownership
MiMedx Group, Inc. has a diverse ownership structure. Institutional investors hold a significant portion of the company's shares, with 424 institutional owners and shareholders holding a total of 116,148,676 shares. Private equity firms hold a 19% stake, while hedge funds control approximately 5.7% of the shares. Individual insiders own about 1.76% of the shares, and the general public holds around 28.1%.
Ask Our Expert AI Analyst
Price Chart
$7.52
